Abstract
Genentech is paying $100 million in up-front and near-term payments to Immunocore to codevelop its experimental cancer therapy IMC-C103C. The drug candidate will be tested in clinical trials next year and targets a cancer antigen called melanoma-associated antigen A4 (MAGE-A4), which is found in multiple types of solid tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
